Then, pharmacological antagonism of CB1R provided therapeutic benefits attenuating progression in bleomycin‐induced PF.[29, 54] Accordingly, CB1R antagonism was identified as a potential therapeutic target for both IPF and HPSPF.[29, 54] First‐generation CB1R antagonist rimonabant was used in the clinic for obesity and metabolic disorders. Here, CNR1 is linked to idiopathic pulmonary fibrosis.